Fluoguide AS (FLUO) - Total Assets
Based on the latest financial reports, Fluoguide AS (FLUO) holds total assets worth Skr29.26 Million SEK (≈ $3.15 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Fluoguide AS (FLUO) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Fluoguide AS - Total Assets Trend (2018–2024)
This chart illustrates how Fluoguide AS's total assets have evolved over time, based on quarterly financial data. Check tangible equity quality of Fluoguide AS to evaluate the tangible quality of the company's equity base.
Fluoguide AS - Asset Composition Analysis
Current Asset Composition (December 2024)
Fluoguide AS's total assets of Skr29.26 Million consist of 93.4% current assets and 6.6% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 65.6% |
| Accounts Receivable | Skr446.00K | 1.6% |
| Inventory | Skr0.00 | 0.0% |
| Property, Plant & Equipment | Skr0.00 | 0.0% |
| Intangible Assets | Skr378.00K | 1.3% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2018–2024)
This chart illustrates how Fluoguide AS's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see FLUO stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Fluoguide AS's current assets represent 93.4% of total assets in 2024, a decrease from 100.0% in 2018.
- Cash Position: Cash and equivalents constituted 65.6% of total assets in 2024, down from 78.7% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, an increase from 0.0% in 2018.
- Asset Diversification: The largest asset category is accounts receivable at 1.6% of total assets.
Fluoguide AS Competitors by Total Assets
Key competitors of Fluoguide AS based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE
|
USA | $763.95 Million |
|
3SBio Inc
F:83B
|
Germany | €36.25 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497
|
China | CN¥4.48 Billion |
|
Novavax Inc
NASDAQ:NVAX
|
USA | $1.04 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Fluoguide AS - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.88 | 11.48 | 1.31 |
| Quick Ratio | 0.88 | 11.48 | 1.31 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Skr-3.64 Million | Skr30.03 Million | Skr3.83 Million |
Fluoguide AS - Advanced Valuation Insights
This section examines the relationship between Fluoguide AS's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 62.09 |
| Latest Market Cap to Assets Ratio | 2.78 |
| Asset Growth Rate (YoY) | -4.2% |
| Total Assets | Skr28.38 Million |
| Market Capitalization | $79.00 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Fluoguide AS's assets at a significant premium (2.78x), suggesting investors see substantial growth potential or unique competitive advantages.
Slight Asset Contraction: Fluoguide AS's assets decreased by 4.2% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Fluoguide AS (2018–2024)
The table below shows the annual total assets of Fluoguide AS from 2018 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | Skr28.38 Million ≈ $3.05 Million |
-4.15% |
| 2023-12-31 | Skr29.61 Million ≈ $3.19 Million |
-16.88% |
| 2022-12-31 | Skr35.62 Million ≈ $3.83 Million |
-33.18% |
| 2021-12-31 | Skr53.31 Million ≈ $5.74 Million |
+218.41% |
| 2020-12-31 | Skr16.74 Million ≈ $1.80 Million |
+219.63% |
| 2019-12-31 | Skr5.24 Million ≈ $563.69K |
+6884.00% |
| 2018-12-31 | Skr75.00K ≈ $8.07K |
-- |
About Fluoguide AS
FluoGuide A/S, a clinical stage biotechnology company, focuses on developing drugs for surgical outcomes by making cancer fluorescent in Denmark. Its lead product candidate is FG001, which is in Phase IIa and IIb for the treatment of high-grade glioma; Phase II clinical trial for the treatment of lung cancer, and head and neck cancer. The company has a collaboration agreement with ZEISS Medical T… Read more